Browsing Category
Pharma Industry News
4750 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Merck KGaA to acquire SpringWorks Therapeutics in $3.9bn rare tumor expansion
Find out how Merck KGaA, Darmstadt, Germany’s $3.9 billion SpringWorks acquisition is reshaping rare tumor treatment and global healthcare leadership.
CG Oncology reports best-in-disease durability data for cretostimogene at AUA 2025
Find out how CG Oncology's cretostimogene data is redefining bladder cancer treatment with best-in-disease durability and strong safety at AUA 2025!
Revolution Medicines’ Zoldonrasib demonstrates early antitumor potential in kras g12d mutant lung cancer at AACR 2025
Find out how Revolution Medicines’ new data on zoldonrasib could reshape KRAS G12D mutant lung cancer treatment strategies.
Abpro and Celltrion reveal promising preclinical results for ABP-102/CT-P72 at AACR 2025
Discover how Abpro and Celltrion’s ABP-102/CT-P72 could reshape HER2 cancer treatment with promising preclinical results. Read the full details now!
Y-mAbs Therapeutics showcases promising CD38-SADA translational pharmacokinetics data at AACR 2025
Find out how Y-mAbs’ CD38-SADA translational pharmacokinetics study at AACR 2025 is advancing next-gen cancer therapies with promising clinical insights.
Johnson & Johnson’s TAR-200 delivers over 80% disease-free survival, offering new hope in BCG-unresponsive high-risk papillary NMIBC
Discover how Johnson & Johnson’s TAR-200 is redefining bladder cancer treatment with over 80% disease-free survival and 94% bladder preservation today!
Keymed Biosciences breaks new ground with CM518D1 IND approval for hard-to-treat gastrointestinal cancers
Discover how Keymed Biosciences' CM518D1 is advancing innovative treatment options for gastrointestinal cancers after IND approval!
Hope for bladder cancer patients? UroGen’s UGN-301 shows strong safety and clinical activity in early trial
Find out how UroGen Pharma’s UGN-301 is offering new hope for bladder cancer patients with promising Phase 1 trial results. Read the latest developments here!
Breakthrough for Wilson disease: Innorna’s IN013 wins dual FDA fast-track approvals
Innorna accelerates mRNA treatment for Wilson Disease with dual FDA designations. Discover how IN013 could transform care for rare genetic disorders!
Pfizer breakthrough: New immunotherapy combo slashes bladder cancer recurrence risk by 32%
Discover how Pfizer’s new sasanlimab combination therapy is redefining treatment for high-risk bladder cancer after 30 years — read the breakthrough results now!